Cannabis
Panaxia and Leriva announced: Exclusive collaborations in Greece
Panaxia Labs Israel, Ltd. (Panaxia Israel) (TASE: PNAX), Israel’s leading medical cannabis products manufacturer and Leriva Group, one of Greece’s leading distributors of medical equipment, medical supplies and health services, announced today, Wednesday May 19, 2021, a binding agreement of manufacture, commercialization and distribution of medical cannabis finished products, developed by Panaxia for medical cannabis patients in Greece.
Under the agreement, Panaxia will be responsible for registering the products, while complying with the European standard requirements, including EU-GMP; developing and manufacturing new and advanced products, including tablets, suppositories (candles) and inhalation products.
Leriva, whose clients include physicians, hospitals and pharmacies, will market, sell, and distribute Panaxia’s premium products under the Panaxir brand to patients, following a doctor’s prescription for labeling prevention and treatment of nausea as a result of taking Anti-Neoplastic drugs; Neuropathic Pain and Cancerous Pain and Spasticity caused by Multiple Sclerosis.
To the best of the companies’ knowledge, up to this date, no medical cannabis product has received a marketing authorization in Greece, despite the fact that the Greek government has approved the regulation of the country’s medical cannabis market in May 2017. Thus, Panaxia, which is the only Israeli company with a European Standard EU-GMP, is expected to be the first company, or among the pioneer companies, to register its products for marketing in Greece.
Panaxia and Leriva anticipate first sales of Panaxir products in Greece during 2022, subject to the completion of the products’ registration for marketing and distribution in Greece. This is in addition to the Panaxia’s premium products export and marketing activities in Germany, France and Cyprus, which began earlier this year.
The agreement will enter into force upon completion of the registration of the first product in Greece.
George Joakimidis, CEO of Leriva Group, said today: “Israel is the pioneer country in the medical cannabis field and Panaxia is its leading ambassador. Medical cannabis is gaining traction across the world and is rapidly becoming more mainstream. The therapeutic benefits of medical cannabis and the treatment options it offers in addressing a wide range of diseases and symptoms are increasingly being embraced by the medical community. Our partnership with Panaxia, an acclaimed pioneer in the field, enables us to be at the forefront of this emerging market. Working jointly with Panaxia, over the ensuing months we expect to file for and obtain the necessary regulatory approvals and once the marketing authorizations have been issued, be in a position to provide an array of medicinal cannabis products to patients and doctors in Greece.”
Dr. Dadi Segal, CEO of Panaxia, said today: “We are proud to partner with Leriva Group, the leading Greek company in the marketing and distribution of medicines and medical technologies, which has chosen Panaxia as its exclusive supplier of premium medical cannabis products to patients in our neighboring Greece. We are excited about the opportunity to take part in the development of the medical cannabis market in the country. The agreement reflects the regulatory and impressive professional reputation we have accumulated in Germany, France and Cyprus, as well as the strategic concept of Panaxia – to penetrate regulated markets in the initial growth stages with a minority of competitors, while establishing market shares”.
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
Cannabis
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
Cannabis
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
transfer1 week ago
IMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis1 week ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
Cannabis1 week ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis1 week ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
CCELL®2 weeks ago
CCELL Launches Environmentally Conscious Eco Star AIO Vaporizer
-
Innocan4 days ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Cannabis3 days ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Curaleaf4 days ago
Curaleaf Completes Acquisition of Northern Green Canada